School of Medicine


Showing 1-50 of 128 Results

  • Fahim Abbasi

    Fahim Abbasi

    Clinical Assistant Professor, Medicine - Cardiovascular Medicine

    BioDr. Fahim Abbasi specializes in diagnosis and treatment of prediabetes and insulin resistance. Dr. Abbasi has a special interest in prevention of diabetes and cardiovascular disease through lifestyle modifications.

  • Kevin M. Alexander, MD, FACC, FHFSA

    Kevin M. Alexander, MD, FACC, FHFSA

    Assistant Professor of Medicine (Cardiovascular Medicine) at the Stanford University Medical Center

    BioDr. Alexander is an advanced heart failure-trained cardiologist. He is also an Assistant Professor of Cardiovascular Medicine at Stanford University School of Medicine.

    Dr. Alexander specializes in the management of advanced heart failure and transplant cases, seeing a wide range of patients. He also has an active research laboratory, studying various forms of heart failure.

    Dr. Alexander has expertise in diagnosing and treating transthyretin cardiac amyloidosis, a critical yet underdiagnosed cause of heart failure among African Americans and the elderly. He is conducting extensive research to enhance our understanding of this condition, with grant support from the National Institutes of Health and American Heart Association, among other sources.

  • Euan A. Ashley

    Euan A. Ashley

    Associate Dean, School of Medicine, Roger and Joelle Burnell Professor of Genomics and Precision Health, Professor of Medicine (Cardiovascular Medicine), of Genetics, of Biomedical Data Science and, by courtesy, of Pathology

    Current Research and Scholarly InterestsThe Ashley lab is focused on precision medicine. We develop methods for the interpretation of whole genome sequencing data to improve the diagnosis of genetic disease and to personalize the practice of medicine. At the wet bench, we take advantage of cell systems, transgenic models and microsurgical models of disease to prove causality in biological pathways and find targets for therapeutic development.

  • Themistocles (Tim) Assimes

    Themistocles (Tim) Assimes

    Associate Professor of Medicine (Cardiovascular Medicine) and, by courtesy, of Epidemiology and Population Health

    Current Research and Scholarly InterestsGenetic Epidemiology, Genetic Determinants of Complex Traits related to Cardiovasular Medicine, Coronary Artery Disease related pathway analyses and integrative genomics, Mendelian randomization studies, risk prediction for major adverse cardiovascular events, cardiovascular medicine related pharmacogenomics, ethnic differences in the determinants of Insulin Mediated Glucose Uptake, pharmacoepidemiology of cardiovascular drugs & outcomes

  • Nitish Badhwar

    Nitish Badhwar

    Clinical Professor, Medicine - Cardiovascular Medicine

    BioNitish Badhwar, MD is Professor of Medicine and Director of Cardiac Electrophysiology Training Program at Stanford University School of Medicine. Dr. Badhwar received his medical degree from Maulana Azad Medical College (University of Delhi, India). After completing his internal medicine training from New York Hospital of Queens (affiliated with Cornell Medical School), he worked as faculty in the Department of Medicine at Hospital of St. Raphael (Yale University School of Medicine). He completed Cardiac Electrophysiology training at UCSF with Dr. Scheinman. After being on faculty at UCSF for 15 years he recently joined the Arrhythmia Service at Stanford Hospital. He is a Fellow of American College of Cardiology and Heart Rhythm Society. He has been named best doctor in cardiac electrophysiology in San Francisco Magazine 3 years in a row (2015-2017). This is nominated by his peers. He was given Excellence in Teaching award in Medical Education by Academy of Medical Educators in 2015. He was an invited speaker at prestigious international meetings including Oriental Congress of Cardiology (OCC) in Shanghai, China; Cardiostim EHRA /Europace in Nice, France; Asia Pacific Heart Rhythm Society (APHRS) in Seoul, S Korea; American Heart Association Annual Scientific Session in New Orleans, LA and Indian Heart Rhythm Society in New Delhi, India.


    Clinical Interest: Dr. Badhwar's clinical interest is in complex catheter ablation procedures including mapping and ventricular tachycardia (VT), atrial fibrillation (AF) and supraventricular tachycardia (SVT) including junctional variants of SVT. He started the epicardial ablation program at UCSF and also worked with Dr. Randall Lee to perform the first percutaneous epicardial left atrial appendage (LAA) ligation in the Bay Area in patients with atrial fibrillation. He has also differentiated himself in the field of electrophysiology by performing hybrid procedures with CT surgeons in patients with AF and VT. He is also involved in device implantation including pacemakers, ICD and biventricular pacing for heart failure.

    Research Interest: Dr. Badhwar has published electrophysiologic characteristics of SVTs including atrial tachycardia arising from the coronary sinus musculature, para-hisian atrial tachycardia, left sided AVNRT, junctional tachycardia and nodofascicular tachycardia. He has also published on the use of nuclear medicine (ERNA) in assessing left ventricular dyssynchrony as well as optimal pacing sties in patients with heart failure requiring biventricular pacing. He has described the unique clinical characteristics of epicardial idiopathic VT arising from the cardiac crux. He has also published clinical outcomes of combining LAA ligation with catheter ablation of atrial fibrillation perform (first in human percutaneous closed chested Maze procedure) and is now part of a multi-center randomized study comparing standard ablation to ablation plus LAA ligation in patients with persistent atrial fibrillation (aMAZE trial).

  • Tina Baykaner

    Tina Baykaner

    Assistant Professor of Medicine (Cardiovascular Medicine)

    BioTina Baykaner is an Assistant Professor in the Department of Internal Medicine, Division of Cardiovascular Medicine and Electrophysiology. Following internal medicine residency, cardiovascular medicine and advanced heart failure fellowship trainings at University of California, San Diego and electrophysiology fellowship at Stanford University, Dr. Baykaner joined Stanford University faculty in 2018. She has published over 200 papers, book chapters and abstracts including over 80 original peer-reviewed articles, and delivered over 40 invited presentations in national and international meetings. She serves as associate editor, section editor and editorial board member of four electrophysiology journals.

    Dr. Baykaner’s current research interests include outcomes research, epidemiology and mechanisms of rhythm disorders. She is currently funded by the National Institutes of Health to study patient related outcomes regarding atrial fibrillation (AF) ablation. She received prior research funding from American Heart Association and Heart Rhythm Society. Dr. Baykaner's clinical practice focuses on ablation of atrial and ventricular arrhythmias, SVTs, inappropriate sinus tachycardia management, device implantation and device extraction.

    Dr. Baykaner is an active member of American Heart Association (AHA), American College of Cardiology (ACC), Heart Rhythm Society (HRS) and European Society of Cardiology (ESC). She serves as an elected member of the Communications Committee for HRS, and previously served as an elected member of the ACC Task Force ICD research committee. She also served in the Organizing Committee for Stanford Cardiovascular Institute Annual Postdoctoral Research Meeting in 2017 and 2018 and for Early Career related sessions for HRS Scientific Sessions in 2019 and 2020.

  • Stephen Chang, MD, PhD

    Stephen Chang, MD, PhD

    Instructor, Biochemistry
    Instructor, Biochemistry
    Instructor, Medicine - Cardiovascular Medicine

    BioPrior to a career in medicine, Dr. Chang was an English major and subsequent novelist at night. During the days, he taught literature part-time at Rutgers University, and for extra money, worked in a laboratory in NYC washing test tubes. Inspired by his laboratory mentor, he began volunteering at the hospital next door, and developed a love for interacting with patients. Through this experience, he saw how caring for others could form deep bonds between people - even strangers - and connect us in a way that brings grandeur to ordinary life.

    In addition to seeing patients, Dr. Chang is a physician-scientist devoted to advancing the field of cardiovascular medicine. His research has been focused on identifying a new genetic organism that better models human heart disease than the mouse. For this purpose, he has been studying the mouse lemur, the smallest non-human primate, performing cardiovascular phenotyping (vital signs, ECG, echocardiogram) on lemurs both in-bred (in France) and in the wild (in Madagascar) to try to identify mutant cardiac traits that may be heritable - and in the process, characterize the first high-throughput primate model of human cardiac disease.

  • Paul Cheng MD PhD

    Paul Cheng MD PhD

    Assistant Professor of Medicine (Cardiovascular Medicine)

    BioDr. Cheng is a Cardiologist at Stanford University School of Medicine in the Department of Medicine and a member of the Cardiovascular Research Institute. Dr. Cheng received his BEng in Chemical Engineering and BSc in biology at MIT. He subsequently completed his MD/PhD at UCSF working in the Srivastava lab studying how extracellular morphogenic signals affect cardiac development and fate determination of cardiac progenitors. Dr. Cheng completed internal medicine residency and cardiology fellowship at Stanford. His current clinical focus is in amyloidosis and cardio-oncology. During his post doctoral research in the Quertermous lab, he pioneered the application of single cell transcriptomic and epigenetic techniques to study human vascular diseases including atherosclerosis and aneurysm, and applied these techniques to investigate molecular mechanisms behind genetic risk factors for several human vascular diseases including atherosclerosis, and aortopathies such as Marfan's and Loey-Dietz syndrome.

    The Cheng lab takes a patient-to-bench-to-bedside approach to science. The lab focuses on elucidating new pathogenic mechanisms of human vascular diseases through combing human genetics and primary vascular disease tissues, with high-resolution transcriptomic and epigenetic profiling to generate novel hypothesis that are then tested in a variety of in vitro and in vivo models. The lab is focused on two broad questions: (1) understanding the biological underpinning of the differences in diseases propensities of different arterial segments in an individual (i.e. why do you have atherosclerosis and aneurysms in certain segments but not others), and (2) understanding the role of perivascular fibroblast in human vascular diseases.

  • Daniel Clark, MD, MPH

    Daniel Clark, MD, MPH

    Clinical Assistant Professor, Medicine - Cardiovascular Medicine
    Clinical Assistant Professor, Pediatrics - Cardiology

    BioDr. Clark is a board-certified, fellowship-trained cardiologist with the Adult Congenital Heart Program at Stanford Health Care. He is also a clinical assistant professor with dual appointments in the Division of Cardiovascular Medicine, Department of Medicine and the Division of Cardiology, Department of Pediatrics at Stanford University School of Medicine.

    Dr. Clark specializes in the diagnosis and treatment of adult congenital heart disease (ACHD) and the management of congenital and acquired heart disease in children. His clinical focus involves the combined use of cardiac magnetic resonance (CMR) and other imaging techniques to evaluate patients with known or suspected cardiovascular disease. Dr. Clark’s extensive training and experience with these techniques include multiple fellowships in adult cardiology, cardiovascular imaging, and ACHD.

    Dr. Clark is currently a co-investigator on multiple research studies. During his fellowship, he received a training grant from the National Institutes of Health enabling evaluation of the ability of CMR to diagnose COVID-19-associated heart inflammation among college athletes. He currently uses CMR to assess heart transplant outcomes in donors positive for hepatitis C virus. Dr. Clark also received a research grant from the Adult Congenital Heart Disease Association supporting a randomized, controlled clinical trial of cardiac rehabilitation among patients with Fontan failure.

    Dr. Clark serves as a peer reviewer for multiple prestigious journals, including The New England Journal of Medicine, Circulation, Journal of the American College of Cardiology, and Journal of the American Heart Association (JAHA). He serves on the editorial board for both JAHA and Circulation: Cardiovascular Imaging. He is also a member of numerous professional medical societies, including the American College of Cardiology, the American Heart Association, and the Adult Congenital Heart Association.

  • Shoa L. Clarke, MD, PhD

    Shoa L. Clarke, MD, PhD

    Assistant Professor of Medicine (Cardiovascular Medicine) and of Pediatrics

    BioDr. Clarke is a preventive cardiologist and a physician-scientist focused on disease prevention. He earned his undergraduate degree in human biology from the Division of Nutritional Sciences at Cornell University before obtaining his MD and PhD (genetics) from Stanford University School of Medicine. He has completed clinical training in internal medicine (Brigham & Women’s Hospital), pediatrics (Boston Children’s Hospital), and cardiovascular medicine (Stanford Hospital), and he is board certified in all three specialties. His research is focused on 1) understanding complex disease genetics in diverse populations, 2) integrating monogenic and polygenic risk with clinical risk, 3) large-scale phenotyping using the electronic health record and medical images. His clinical practice focuses on identifying risk factors for cardiovascular disease with the goal of promoting health and longevity through evidence-based personalized treatment. He is interested in developing family-centric approaches for the treatment of adults and children carrying genetic risk for disease.

  • William Clusin, MD

    William Clusin, MD

    Associate Professor of Medicine (Cardiovascular Medicine)

    Current Research and Scholarly InterestsCardiac action potentials; tissue culture, voltage, clamp technique; role of calcium in ischemia arrhythmias; coronary, artery disease; myocardial infarction.

  • John P. Cooke, MD, PhD

    John P. Cooke, MD, PhD

    Professor of Medicine (Cardiovascular Medicine), Emeritus

    Current Research and Scholarly InterestsOur translational research program in vascular regeneration is focused on generating and characterizing vascular cells from human induced pluripotential stem cells. We are also studying the therapeutic application of these cells in murine models of peripheral arterial disease. In these studies we leverage our longstanding interest in endothelial signaling, eg by nitric oxide synthase (NOS) as well as by nicotinic cholinergic receptors (nAChR).

  • Rajesh Dash, MD PhD;      Director of SSATHI & CardioClick

    Rajesh Dash, MD PhD; Director of SSATHI & CardioClick

    Associate Professor of Medicine (Cardiovascular Medicine)

    Current Research and Scholarly InterestsI have two research areas:
    1) Heart disease in South Asians - genetic, metabolic, & behavioral underpinnings of an aggressive phenotype.

    2) Imaging cell injury & recovery in the heart. Using Cardiac MRI to visualize signals of early injury and facilitating preventive medical therapy. Optimizing new imaging methods for viable cells to delineate live heart cells or transplanted stem cells.

  • Rajiv Doshi, MD

    Rajiv Doshi, MD

    Adjunct Professor and Director, India Biodesign Program, Medicine - Cardiovascular Medicine

    Current Research and Scholarly InterestsDr. Rajiv Doshi serves as an Adjunct Professor of Medicine and as the Director of the India Program at the Byers Center for Biodesign. Dr. Doshi is also the co-Director of the India-based Founders Forum, an executive education training program for India’s leading health technology entrepreneurs. He has also advised the Government of India and various Indian state governments in the development of policies that support Indian health technology innovation.

  • Ramzi Emanuel Dudum

    Ramzi Emanuel Dudum

    Clinical Scholar, Medicine - Cardiovascular Medicine
    Postdoctoral Scholar, General Internal Medicine
    Masters Student in Health Policy, admitted Autumn 2022

    BioDr. Dudum is a cardiologist, public health specialist, and outcomes researcher working to develop novel risk prediction methods and implementation strategies to create practices and systems that allow for reductions in cardiovascular disease. He completed a Masters in Public Health at Johns Hopkins concentrating in epidemiology and biostatistics and a Doctorate of Medicine at George Washington University. He is currently a candidate for a Masters of Science in Health Policy at Stanford.

    He completed internal medicine residency training as part of the Osler Medical Service, where he worked under the mentorship of Drs. Roger Blumenthal and Michael Blaha to study improving cardiovascular risk prediction and coronary artery calcium. Given his focus on population health and implementation science, he also helped launch and refine risk adjustment tools and implemented guideline-directed medical care pathways. During his time there, he was recognized for his clinical acumen and dedication to patient care.

    He came to Stanford for his cardiovascular medicine fellowship and continued research in coronary artery calcium under the mentorship of Drs. David Maron and Fatima Rodriguez while also conducting cardiovascular health implementation science work under the mentorship of Dr. Steve Asch. He serves as the co-investigator of a prospective randomized trial testing the effects of notification of incidental coronary artery calcium on statin initiation rates among those with and without cardiovascular disease (NCT 05588895). He has worked with hospital leaders to implement digital health and artificial intelligence tools, creating the infrastructure for the prospective use of AI-algorithms on radiology studies. As a preventive cardiologist and population health specialist, he leads efforts in the preventive cardiology section related to improving cardiovascular health.

  • Zachary Edmonds, MD, MBA

    Zachary Edmonds, MD, MBA

    Adjunct Professor, Medicine - Cardiovascular Medicine

    BioAdjunct Professor of Medicine | Cardiovascular Medicine | Stanford Medicine

    Seasoned clinician with a proven track record of mentoring medtech entrepreneurs and early stage companies in the development of life changing technologies. As the Associate Director of the PAMF Hospital Medicine service line he co-leads a team of 30 physicians across 3 community hospitals in the Bay Area. When not seeing patients, he serves as the Chief Medical Officer at Fogarty Innovation where he mentors a variety of early stage companies. As an Adjunct Professor of Medicine at Stanford he works closely with the Biodesign group to teach and mentor students and Biodesign fellows. He co-teaches the Biodesign Innovation graduate course which is offered to Stanford graduate students in the school of medicine, school of engineering and the graduate school of business each winter and spring quarter. Zach holds an MD from the UCLA School of Medicine and an MBA from the UCLA Anderson School of Management. He completed Internal Medicine Residency and the Biodesign Fellowship at Stanford University.

  • William Fearon, MD

    William Fearon, MD

    Professor of Medicine (Cardiovascular Medicine)

    Current Research and Scholarly InterestsDr. Fearon's general research interest is coronary physiology. In particular, he is investigating invasive methods for evaluating the coronary microcirculation. His research is currently funded by an NIH R01 Award.

  • Peter Fitzgerald, MD, PhD

    Peter Fitzgerald, MD, PhD

    Professor (Research) of Medicine (Cardiovascular), Emeritus

    BioDr. Peter Fitzgerald is the Director of the Center for Cardiovascular Technology and Director of the Cardiovascular Core Analysis Laboratory (CCAL) at Stanford University Medical School. He is an Interventional Cardiologist and has a PhD in Engineering. He is Professor in both the Departments of Medicine and Engineering (by courtesy) at Stanford. Presently, Dr. Fitzgerald’s laboratory includes 17 postdoctoral fellows and graduate engineering students focusing on state-of-the-art technologies in Cardiovascular Medicine. He has led or participated in over 175 clinical trials, published over 550 manuscripts/chapters, and lectures worldwide. He has trained over 150 post-docs in Engineering and Medicine in the past decade. In addition, he heads the Stanford/Asia MedTech innovation program.
    Dr. Fitzgerald has been principle/founder of twenty-one medical device companies in the San Francisco Bay Area. He has transitioned fourteen of these start-ups to large medical device companies. He serves on several boards of directors, advised dozens of medical device startups as well as multinational healthcare companies in the design and development of new diagnostic and therapeutic devices in the cardiovascular arena. In 2001, Peter was on the founding team of LVP Capital, a venture firm, focused on medical device and biotechnology start-ups in San Francisco. In 2009, he co-founded TriVentures, which is an incubator/venture fund for early stage medical technology in Israel.

  • Michael B. Fowler, MBBS, FRCP

    Michael B. Fowler, MBBS, FRCP

    Professor of Medicine (Cardiovascular), Emeritus

    Current Research and Scholarly InterestsAdrenergic nervous system; beta-adrenergic function in, heart failure; drugs in heart failure.

  • Victor Froelicher, MD

    Victor Froelicher, MD

    Professor of Medicine (Cardiovascular) at the Veterans Affairs Palo Alto Health Care System, Emeritus

    Current Research and Scholarly InterestsScreening of athletes for sudden cardiac death, Computerized ECG and clinical data management; exercise Physiology including expired gas analysis; the effect of chronic and acute exercise on the heart; digital recording of biological signals; diagnostic use of exercise testing; development of Expert Medical System software and educational tools.

  • Daniel Aaron Gerber, MD

    Daniel Aaron Gerber, MD

    Clinical Assistant Professor, Medicine - Cardiovascular Medicine

    BioDr. Gerber is a critical care cardiologist and co-director of Stanford's Cardiac ICU. He has dual subspecialty training in cardiovascular and critical care medicine and additional board certification in echocardiography. He completed his residency in internal medicine, fellowship in cardiovascular medicine, and an additional fellowship in critical care medicine at Stanford University and joined as faculty in 2021 as a Clinical Assistant Professor in the Department of Medicine’s Division of Cardiovascular Medicine.

    Dr. Gerber manages the full spectrum of heart and vascular conditions with a focus on critically ill patients with life-threatening cardiovascular disease. He is active in medical education, teaching introductory echocardiography to Stanford medical students and residents, co-directing the Stanford Critical Care Medicine Critical Care Ultrasound Program, and lecturing nationally on critical care echocardiography and point-of-care ultrasonography at the Society of Critical Care Medicine’s annual congress. Finally, Dr. Gerber’s research interests focus on optimizing cardiac intensive care, including working with the Critical Care Cardiology Trials Network (CCCTN) - a national network of tertiary cardiac ICUs coordinated by the TIMI Study Group - and studying acute mechanical circulatory support techniques to improve patient outcomes and care processes.

  • Francois Haddad

    Francois Haddad

    Clinical Professor, Medicine - Cardiovascular Medicine

    BioDr. Francois Haddad, MD is a Clinical Professor of Medicine that specializes in the field of cardio-vascular imaging, pulmonary hypertension, advanced heart failure and transplantation. Dr. Haddad has over 18 years of practice in the field of cardiology. He directs Stanford Cardiovascular Institute Biomarker and Phenotypic Core Laboratory dedicated to translational studies in cardiovascular medicine. The laboratory focuses on (1) identifying early biomarkers of heart failure and aging, (2) bioengineering approaches to cardiovascular disease modeling and (3) novel informatic approach for the detection and risk stratification of disease. He is involved is several precision medicine initiatives in health including the Project Baseline, the Integrated Personalized Omics Profiling Initiative, the Athletic screening program at Stanford and the Strong-D cardiac rehabilitation initiative in individuals with diabetes mellitus.

  • William Haskell

    William Haskell

    Professor (Research) of Medicine, Emeritus

    Current Research and Scholarly InterestsMy major research interests and activities over the next several years will focus on the development and evaluation of the objective measurement of physical activity in free-living populations using a variety of sensing devices and mobile phones for data collection and processing. Also, I will continue to direct the Stanford Heart Network with the major mission being to assist community-based CVD prevention/treatment programs implement more effective heart attack and stroke prevention programs.

  • Paul Heidenreich, MD

    Paul Heidenreich, MD

    Professor of Medicine (Cardiovascular)

    Current Research and Scholarly InterestsMy research interests include

    1) The cost-effectiveness of new cardiovascular technologies.
    Example: tests to screen asymptomatic patients for left ventricular systolic dysfunction.

    2) Interventions to improve the quality of care of patients with heart disease. Examples: include clinical reminders and home monitoring.

    3) Outcomes research using existing clinical and administrative datasets.

    4) Use of echocardiography to predict prognosis (e.g. diastolic dysfunction).

  • Mark Hlatky, MD

    Mark Hlatky, MD

    Professor of Health Policy, of Medicine (Cardiovascular Medicine) and, by courtesy, of Epidemiology and Population Health
    On Partial Leave from 09/01/2023 To 08/31/2024

    Current Research and Scholarly InterestsMy main research work is in "outcomes research", especially examining the field of cardiovascular medicine. Particular areas of interest are the integration of economic and quality of life data into randomized clinical trials, evidence-based medicine, decision models, and cost-effectiveness analysis. I am also interested in the application of novel genetic, biomarker, and imaging tests to assess risk and guide clinical management of coronary artery disease.

  • Benjamin Davies Horne

    Benjamin Davies Horne

    Adjunct Clinical Associate Professor, Medicine - Cardiovascular Medicine

    BioDr. Benjamin Horne is an Adjunct Clinical Associate Professor who is based at the Intermountain Medical Center Heart Institute in Salt Lake City, UT, where he serves as the Director of Cardiovascular and Genetic Epidemiology. His doctoral training (PhD) in genetic epidemiology was completed at the University of Utah and he holds masters degrees in public health and in biostatistics. Dr. Horne is a fellow of the American Heart Association, a fellow of the American College of Cardiology, and a member of the American Society of Human Genetics. Dr. Horne’s research focuses on population health and precision medicine, including evaluating the genetic epidemiology of heart diseases, developing and implementing clinical decision tools for personalizing medical care, discovering the human health effects of intermittent fasting, and studying the influences of air pollution on major adverse health events.

  • Stephanie Hsiao, MD

    Stephanie Hsiao, MD

    Clinical Assistant Professor, Medicine - Cardiovascular Medicine

    BioDr. Stephanie Hsiao is a clinical assistant professor at Stanford Medicine and a full-time advanced heart failure/transplant cardiologist at the Palo Alto VA. She grew up in Taipei, Taiwan. She attended undergraduate at UC Berkeley and obtained her Master’s degree in Pharmacology at Cambridge University in the UK. She obtained her M.D. from UC San Francisco. She completed her Internal Medicine residency and General Cardiology fellowship at the California Pacific Medical Center in San Francisco, where she served as the chief resident and chief cardiology fellow. She completed her advanced heart failure/transplant cardiology fellowship at Stanford in June 2022 and joined the Stanford Faculty soon after. She has a strong interest in medical education and quality improvement. Her clinical interests include HF outreach in the VA health care systems, women’s heart health, and AHFTX fellowship curriculum design/development. Her research interests include multi-organ transplantations and advocacy of diversity-equity-inclusion in advanced HF therapies. She plans to lead a career in medical education and quality improvement to deliver exceptional and equitable care for patients needing advanced HF therapies.

  • Gentaro Ikeda

    Gentaro Ikeda

    Instructor, Medicine - Cardiovascular Medicine

    BioDr. Ikeda is a physician-scientist who develops innovative diagnostic and therapeutic modalities for patients with cardiovascular disease. Based on his clinical experience as a cardiologist, he has become aware of major clinical shortcomings, specifically in the current pharmaceutical therapies for myocardial infarction (MI) and chronic heart failure (HF). Some evidence-based drug therapies, including β-blockers, ivabradine, and renin-angiotensin-aldosterone antagonists are difficult to apply to critical patients due to adverse side effects. Drugs that have shown efficacy in basic animal experiments have failed to show significant benefits in clinical trials. To address these problems, he moved to academia to conduct translational research. During his graduate training in the Egashira Lab, he focused on drug delivery systems (DDS) that target mitochondria in animal models of MI. He obtained advanced skills in molecular biology, mitochondrial bioenergetics, and animal surgery. He realized the importance of translational research and the great potential of DDS to overcome many clinical problems. He developed nanoparticle-mediated DDS containing cyclosporine for the treatment of patients with MI. He published a first-author paper and received academic awards for his novel science. Since becoming a postdoctoral fellow in the Yang Lab, he has continued to build upon his previous training in translational research. He is currently developing an innovative therapy, namely, extracellular vesicles-mediated mitochondrial transfer for mitochondria-related diseases such as heart failure and mitochondrial disease.

  • Roy Mattathu John, MD, PhD, FRCP

    Roy Mattathu John, MD, PhD, FRCP

    Clinical Professor, Medicine - Cardiovascular Medicine

    BioDr. John is a fellowship-trained cardiologist with more than 25 years of experience. He is a clinical professor in the Department of Medicine at Stanford University School of Medicine.

    He originally earned board certification in clinical cardiac electrophysiology in 1996 and has continued to recertify. He also has earned board certification in cardiovascular disease and internal medicine.

    Dr. John diagnoses and manages all forms of cardiac arrhythmias including atrial fibrillation and ventricular arrhythmias. His special interests include catheter ablation for SVT, atrial arrhythmias, pacemaker and defibrillator implants, and lead extraction.

    He has conducted extensive research. He has participated in large multi-center clinical trials, including over 30 studies as a primary investigator of drugs, devices, and ablation techniques. He helped pioneer a new way to manage scar-related ventricular tachycardia. He also helped develop innovations in cardiac pacemaker technology.

    Dr. John has authored over 200 publications that include 126 original research papers. They have appeared in reputed journals such as the New England Journal of Medicine, Circulation, Lancet, Journal of the American College of Cardiology, European Heart Journal, Heart Rhythm, Journal of Cardiovascular Electrophysiology, and many more. Topics have included innovative, new techniques and technologies for the treatment of supraventricular arrhythmias, atrial fibrillation, ventricular tachycardia, catheter ablation, lead extraction, cardiac pacing, and defibrillation.

    He was a member of the editorial board for Circulation and is currently on the editorial board of the publications Heart Rhythm Journal, Arrhythmia and Electrophysiology, Journal of Cardiac Electrophysiology, and Journal of Innovations in Cardiac Rhythm Management.

    Dr. John also has written several chapters for medical textbooks such as Harrison’s Principles of Internal Medicine, Zipes Textbook on Cardiac Electrophysiology - Cell to Bedside, Conn’s Current Therapy, Electrical Disorders of the Heart, Cardiac Mapping, and many more.

    He has made invited presentations to his peers at scientific sessions of the Heart Rhythm Society, American Heart Association, American College of Cardiology, and Heart Failure Society. He has delivered more than 60 national and international lectures. Subjects include cardiac pacing, defibrillation, heart failure, and arrhythmia management including catheter ablation for arrhythmias.

    Dr. John is a fellow of the American College of Cardiology, Heart Rhythm Society, and Royal College of Physicians of London.

    He has volunteered his time and expertise to provide free cardiac care to underserved patients in Bolivia, India, and Kenya.

  • Neil M. Kalwani

    Neil M. Kalwani

    Clinical Instructor, Medicine - Cardiovascular Medicine

    BioNeil Kalwani, MD, MPP is a Clinical Instructor in the Division of Cardiovascular Medicine and Director of Preventive Cardiology at the VA Palo Alto Health Care System. He attended college at Yale University and completed graduate degrees in medicine and public policy at Harvard University. He trained in internal medicine at Brigham and Women’s Hospital before arriving at Stanford in 2018 for fellowship in cardiovascular medicine, during which he served as Chief Fellow. He then completed a postdoctoral fellowship through the Stanford-AHRQ Health Services Research Training Program in the Department of Health Policy. His clinical focus is in general and preventive cardiology and echocardiography. He practices at the VA Palo Alto Health Care System and at Stanford Health Care.

    Dr. Kalwani's research focuses on the evaluation of policies and care delivery innovations designed to improve the value of care for patients with cardiovascular disease.

  • Guson Kang

    Guson Kang

    Clinical Assistant Professor, Medicine - Cardiovascular Medicine

    BioDr. Kang is an interventional cardiologist who specializes in the treatment of structural heart disease. He has expertise in complex coronary interventions, transcatheter aortic and mitral valve replacements, transcatheter mitral valve repair, left atrial appendage occlusion, PFO/septal defect closure, alcohol septal ablation, and paravalvular leak closure.

    A Bay Area native, he graduated from Stanford University and obtained his medical degree at Yale University. He came back to Stanford to train in internal medicine, cardiology, and interventional cardiology before completing an advanced structural interventions fellowship at Ford Hospital.

  • Michael S. Kapiloff, MD, PhD

    Michael S. Kapiloff, MD, PhD

    Reinhard Family Professor, Professor (Research) of Ophthalmology and, by courtesy, of Medicine (Cardiovascular Medicine)

    Current Research and Scholarly InterestsDr. Michael S. Kapiloff is a faculty member in the Departments of Ophthalmology and Medicine (Cardiovascular Medicine) and a member of the Stanford Cardiovascular Institute. Although Dr. Kapiloff was at one time a Board-Certified General Pediatrician, he is currently involved in full-time basic science and translational research. His laboratory studies the basic molecular mechanisms underlying the response of the retinal ganglion cell and cardiac myocyte to disease. The longstanding interest of his laboratory is the role in intracellular signal transduction of multimolecular complexes organized by scaffold proteins. Recently, his lab has also been involved in the translation of these concepts into new therapies, including the development of new AAV gene therapy biologics for the prevention and treatment of heart failure and for neuroprotection in the eye.

    URL to NCBI listing of all published works:
    http://www.ncbi.nlm.nih.gov/sites/myncbi/michael.kapiloff.1/bibliography/40252285/public/?sort=date&direction=descending

    For more information see Dr. Kapiloff's lab website: http://med.stanford.edu/kapilofflab.html

  • Daniel Katz

    Daniel Katz

    Instructor, Medicine - Cardiovascular Medicine

    BioDaniel Katz is an Instructor of Medicine and an Advanced Heart Failure and Transplant Cardiologist. He completed internal medicine residency at Massachusetts General Hospital, general cardiology training at Beth Israel Deaconess Medical Center, and then joined Stanford in 2021 for his advanced heart failure training. Since medical school, his research has focused on identifying the various pathophysiologic patterns and mechanisms that lead to the heterogeneous syndrome of heart failure. His efforts leverage high dimensional data in many forms including clinical phenotypes, plasma proteomics, metabolomics, and genetics. He is presently engaged in analysis of multi-omic data from the Molecular Transducers of Physical Activity Consortium (MoTrPAC) and the NHLBI Trans-Omics for Precision Medicine (TOPMed) Program. His clinical interests include advanced heart failure, transplant cardiology, and mechanical circulatory support.

  • Masataka Kawana

    Masataka Kawana

    Assistant Professor of Medicine (Cardiovascular Medicine)

    BioDr. Kawana joined the Advanced Heart Failure and Transplant Cardiology group in 2018. He completed his internal medicine, cardiovascular medicine, and heart failure training at Stanford. He also completed a postdoctoral research fellowship under Dr. James Spudich in the Department of Biochemistry. He sees advanced heart failure patients in the clinic and attends CCU/heart failure service, and post-heart transplant and MCS service. His research interests are in the fundamental mechanism of inherited cardiomyopathies, and he studies the effect of gene mutation on the cardiac sarcomere function using cutting-edge biochemical and biophysical approaches, which would lead to the development of novel pharmacotherapy that directly modulates cardiac muscle protein. He is involved in multiple clinical trials for pharmacotherapy in inherited cardiomyopathy and also conducting a device study in heart failure.